PATENT CLAIM ANALYSIS

Application Number: 16038739
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "093000"]

Abstract:
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Claim (Index 45):
A method of treating idiopathic pulmonary fibrosis (IPF) in a mammal comprising administering a therapeutically effective amount of a compound, or a stereoisomer or pharmaceutically acceptable salt thereof, to the mammal in need thereof, wherein the compound is represented by formula:

Metadata:
- Claim Count in Document: 35.0
- Percentile: 95.0
- Lexical Diversity: 1.2
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15628104', '15323967', '15534105', '14352554', '14488294']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7056702754641438
- 35 USC 102 Novelty (BERT): 0.5591056389029848
- Combined Prediction Score: 0.6910138118080279
- Mean Citation Score: 310.378278
- Max Citation Score: 437.55276
- Similarity Product: 304.6656786714864

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test